RetaCalc
Protocol library
BlendNot ApprovedMixedVery Low confidenceSourced

KLOW blend

A four-component GHK-Cu, BPC-157, KPV and TB-500 research blend with no controlled human evidence for the combined formulation.

Evidence context, not a personal protocol

Quantities below reproduce their stated source context—label, human study, laboratory work or educational guide. They do not assess suitability, product equivalence or individual risk.

Dosage and protocol evidence

Each card states what the quantities are based on. A third-party or animal schedule is not a validated human dose.

Community GuideSubcutaneous in guideDaily
Third-party educational schedule for an 80 mg KLOW blend

Weeks 1-2 use 1.25 mg GHK-Cu plus 250 mcg each of BPC-157, KPV and TB-500 daily; weeks 3-4 double those amounts; weeks 5-8 use 3.75 mg plus 750 mcg each; weeks 9-12 return to the week 3-4 quantities

These quantities are calculated from the stated 50:10:10:10 blend ratio. No controlled human study validates the mixture or progression.

View source

Evidence summary

A four-component GHK-Cu, BPC-157, KPV and TB-500 research blend with no controlled human evidence for the combined formulation.

Protocol basis

No matched clinical protocol was found for this named combination. Component literature is displayed only to explain why it cannot validate the blend.

What remains uncertain

Compatibility, stability, combined pharmacology, systemic safety and clinically meaningful outcomes are unknown.

Warnings and contraindications

No controlled human study of the four-component blend was identified.
KPV human evidence concerns a related oral analogue rather than this mixture.
Adding components multiplies unresolved formulation, interaction and exposure questions.